Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 17

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 17
---
 served on the board at Viracta Therapeutics, Inc. (formerly Sunesis Pharmaceuticals, Inc.). Dr. Onetto received a B.A. from the University of Paris, an M.Sc. in Pharmacology from the Université of Montréal, and an M.D. and a Hematology-Oncology Certificate from the University of Paris. We believe that Dr. Onetto is qualified to serve on our Board due to her extensive experience in clinical development and translational research.

<div align='center'>8</div>

Board Diversity The Board diversity matrix, below, provides the diversity statistics for our Board. Our previous year’s disclosure can be found in our definitive proxy statement filed with the SEC on April 26, 2024. Board Diversity Matrix (As of April 15, 2025)

| Total Number of Directors               |      6 |      |
|                                         | Female | Male |
| Part I: Gender Identity                 |        |      |
| Directors                               |      3 |    3 |
| Part II: Demographic Background         |        |      |
| African American or Black               |      — |    — |
| Alaskan Native or Native American       |      — |    — |
| Asian                                   |      — |    — |
| Hispanic or Latinx                      |      — |    — |
| Native Hawaiian or Pacific Islander     |      — |    — |
| White                                   |      3 |    3 |
| Two or More Races or Ethnicities        |      — |    — |
| LGBTQ+                                  |      — |      |
| Did Not Disclose Demographic Background |      — |      |

<div align='center'>9

information regarding the board of directors and corporate governance</div>

Independence of The Board of Directors

As required under the Nasdaq Stock Market, or Nasdaq, listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. The Board consults with our counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that